Results 191 to 200 of about 17,703,275 (296)

Discovery of enaminone-linked benzofuran derivatives as dual VEGFR-2/hCA IX inhibitors exhibiting hypoxia-mediated chemosensitization. [PDF]

RSC Med Chem
Eldehna WM, Elsayed ZM, Elnagar MR, Ammara A, Elkotamy MS, Monir R, Nocentini A, Al-Sanea MM, Supuran CT, Tawfik HO, Abdel-Aziz HA, Negmeldin AT.   +11 more
europepmc   +1 more source

Immunolocalization of VEGF, VEGFR-1 and VEGFR-2 in lung tissues after acute hemorrhage in rats

In treatment of hypovolemia it is important to reestablish normal tissue hemodynamics after fluid resuscitation. Vascular endothelial growth factor (VEGF) and VEGF receptors (VEGFR) have been identified as important in many physiological and pathological,
Ekerbicer, N, Barut, T, Inan, S, Tarakci, F   +3 more
core  

Leptin in Obesity‐Related Heart Failure: Pathophysiological Mechanisms and Therapeutic Implications

Comprehensive Physiology, Volume 16, Issue 3, June 2026.
Obesity‐associated adipose tissue dysfunction leads to hyperleptinemia and altered leptin signaling. Through Ob‐Rb/LepR‐mediated pathways, leptin may contribute to neurohormonal activation, endothelial dysfunction, inflammation, oxidative stress, and myocardial remodeling.
Xuemin Li, Weiguo Wang, Yibo Zhang, Pengfei Ding, Xuewen Li   +4 more
wiley   +1 more source

Structure-Guided Design of Benzothiazole and Benzimidazole-Based Urea Derivatives Curtailing Oncogenic Signaling via Concurrent Inhibition of VEGFR-2, EGFR, and c‑Met. [PDF]

ACS Omega
Shaheen S, Siddique A, Iftikhar A, Faisal A, Rehman HM, Murtaza G, Tahir A, Saeed A, Hassan A, Rashid U.   +9 more
europepmc   +1 more source

Pharmacokinetic Drug–Drug Interaction Potential of Oral Anticancer Drugs

Clinical Pharmacology &Therapeutics, Volume 119, Issue 6, Page 1614-1627, June 2026.
Drug–drug interaction (DDI) management is critical for safe and effective use of oral anticancer drugs (OADs). Our study objectives were to (i) compile clinically relevant pharmacokinetic (PK) DDI mechanisms for OADs and (ii) assess the prevalence of PK potential DDIs (PDDIs) in patients with advanced solid cancers.
Fatimah Alhurayri, Islam R. Younis, Shadia I. Jalal, Theodore F. Logan, Rohan Maniar, Steven M. Bray, Sara K. Quinney, Zeruesenay Desta, Todd C. Skaar, James E. Tisdale, Tyler Shugg   +10 more
wiley   +1 more source

Multimodal characterization of a pyrazolo[3,4-<i>b</i>]pyridine aldehyde: quantum chemical insights, NLO activity and VEGFR-2 docking/molecular dynamics. [PDF]

RSC Adv
Acosta-Quiroga K, Jiménez CA, Cobos-Montes K, Rodríguez-Núñez YA, López J, Guerra C, Calderón Orjuela DA, Gutierrez M, Polo-Cuadrado E.   +8 more
europepmc   +1 more source

Fusobacterium nucleatum in cancer: Interactions with microbiota, tumour colonisation and cancer progression

Clinical and Translational Medicine, Volume 16, Issue 6, June 2026.
F. nucleatum colonises tumours through mucosal translocation, adjacent‐tissue migration and hematogenous dissemination. It promotes cancer progression via adhesion, inflammation, immune evasion, epigenetic remodelling and metastasis. Its effects on therapy response are tumour‐context dependent. Microbiome‐guided targeting may enable precision oncology.
Feng Zhao, Rui An, Shaobo Yu, Yilei Ma, Wangwang Liu, Caixia Sheng, Xinyou Xie, Jun Zhang   +7 more
wiley   +1 more source

RETRACTION: Licoflavone A Suppresses Gastric Cancer Growth and Metastasis by Blocking the VEGFR-2 Signaling Pathway. [PDF]

J Oncol
Oncology JO.
europepmc   +1 more source

B-Raf/VEGFR-2 Inhibitor RAF265 [PDF]

, 2020
openaire   +1 more source

VEGFR-2-Inhibition bei fortgeschrittenem Magenkarzinom [PDF]

Im Focus Onkologie, 2015
openaire   +1 more source